论文部分内容阅读
诺华公司在 2 0 0 1～ 2 0 0 2年计划上市 6个新产品。除了处于研究后期的产品 ,公司也公布了处于开发初期的产品进展。计划 2 0 0 1年上市的产品有治疗过敏性肠综合征的ｔｅｇａｓｅｒｏｄ(Ｚｅｌｍａｃ) ;治疗哮喘和过敏性鼻炎的ｏｍａｌｉｚｕｍａｂ(Ｘｏｌａｉｒ)。公司同
Novartis planned to list six new products in the year 2000–2000. In addition to products in the later stages of research, the company also announced product development in the early stages of development. The products that were planned for market in 2010 are tegastero (Zelmac) for the treatment of irritable bowel syndrome and omalizumab (Xolair) for the treatment of asthma and allergic rhinitis. Company with